Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Leuk Lymphoma ; 50(10): 1566-72, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19863335

ABSTRACT

Many patients who undergo hematopoietic cell transplantation (HCT) present with anemia and have received red blood cell transfusions before HCT. As a result, iron overload is frequent and appears to be particularly prominent in patients with myelodysplastic syndromes. There is evidence that peritransplant events contribute to further iron accumulation, although the mechanism that disrupts normal iron homeostasis remains to be determined. Recent studies suggest that iron overload, as determined by ferritin levels, a surrogate marker for iron, is a risk factor for increased non-relapse mortality after HCT. Iron overload is associated with an increased rate of infections, in particular with fungal organisms. Furthermore anecdotal data suggest that increased hepatic iron may mimic the clinical picture of (chronic) graft-versus-host-disease (GVHD). Whether excess iron contributes to GVHD and whether iron depletion, be it by phlebotomy or chelation, reduces the post-transplantation complication rate and improves transplant outcome is yet to be determined.


Subject(s)
Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation , Iron Overload/etiology , Postoperative Complications/etiology , Anemia/etiology , Anemia/therapy , Animals , Apoptosis , Chelation Therapy , Diagnosis, Differential , Erythrocyte Transfusion/adverse effects , Graft vs Host Disease/diagnosis , Graft vs Host Disease/physiopathology , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infections/etiology , Intestinal Absorption , Iron Overload/diagnosis , Iron Overload/drug therapy , Iron Overload/therapy , Iron, Dietary/pharmacokinetics , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred Strains , Mice, SCID , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/surgery , Phlebotomy , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/therapy , Transferrin/metabolism , Transferrin/therapeutic use , Transplantation Conditioning/adverse effects
3.
Biol Blood Marrow Transplant ; 8(7): 360-7, 2002.
Article in English | MEDLINE | ID: mdl-12171482

ABSTRACT

This study investigates the potential role of the recombinant c-mpl ligands (recombinant human thrombopoietin [rhTPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rhMGDF]) on the recovery of platelet counts after TBI with and without allogeneic hematopoietic stem cell transplantation (HSCT) in an established canine model. Initially, 3 cohorts, each with 2 nonirradiated dogs, received increasing doses of rhTPO (5 microg/kg per day; 10 microg/kg per day; 20 microg/kg per day) for 7 days to determine the optimal dose. The dose of 10 microg/kg per day of rhTPO was selected for subsequent studies. Ten dogs then received either rhTPO or placebo for 28 days after 200 cGy TBI without HSCT. The rhTPO group had fewer days with platelet counts <20,000/microL (9.8 days versus 17.8 days, P < .05) and significantly increased granulocyte counts (n = 5) compared to the controls (n = 5). RhTPO-specific antibodies developed in 2 dogs, which caused a significant but transient decrease of the platelet counts. Retreatment of these sensitized dogs with rhTPO resulted in profound transient decreases in platelet counts. In the next study, 20 dogs received either PEG-rhMGDF or placebo for 21 days after 920 cGy TBI and allogeneic HSCT. The median time to platelet recovery (>20,000/microL) for the PEG-rhMGDF group (n = 10) was 14.0 days compared to 15.5 days for the control group (n = 10; log rank, P = .35). There were no significant differences in the total time to platelet counts <20,000/microL or in the time to recover neutrophil counts >500/microL. The effects of rhTPO on recovery of platelet and granulocyte counts after sublethal TBI were modest, and no effects of PEG-rhMGDF were observed on hematopoietic recovery after high-dose TBI and allogeneic HSCT. The significant effect that rhTPO-specific antibodies had on the platelet counts may limit the clinical role of recombinant c-mpl ligands unless sensitization can be prevented.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Thrombopoietin/pharmacology , Whole-Body Irradiation/adverse effects , Animals , Blood Platelets/drug effects , Blood Platelets/radiation effects , Bone Marrow Transplantation/methods , Combined Modality Therapy , Dogs , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Evaluation, Preclinical , Hematopoiesis/drug effects , Hematopoiesis/radiation effects , Isoantibodies/blood , Platelet Count , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/pharmacology , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Thrombocytopenia/etiology , Thrombocytopenia/prevention & control , Thrombopoietin/administration & dosage , Thrombopoietin/immunology , Transplantation, Homologous/methods
SELECTION OF CITATIONS
SEARCH DETAIL